Sanofi and Regeneron Pharmaceuticals Inc. said there are about 75,000 adults in the U.S. living with prurigo nodularis who are most in need of a new treatment option. "Sanofi, Regeneron Say Dupixent Gets FDA Approval to Treat Prurigo Nodularis Skin Disease," at 6:35 p.m. ET Sept. 28, incorrectly said the companies said there are about 75,000 adults in the U.S. living with prurigo nodularis.

 

(END) Dow Jones Newswires

September 30, 2022 14:56 ET (18:56 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi Charts.